CLINICAL TRIALS PROFILE FOR TIVDAK
✉ Email this page to a colleague
All Clinical Trials for TIVDAK
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03245736 ↗ | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Completed | Genmab | Phase 2 | 2017-08-23 | The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin. |
NCT03245736 ↗ | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Completed | Seagen Inc. | Phase 2 | 2017-08-23 | The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin. |
NCT03438396 ↗ | A Trial of Tisotumab Vedotin in Cervical Cancer | Active, not recruiting | Belgian Gynaecological Oncology Group | Phase 2 | 2018-06-12 | A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. |
NCT03438396 ↗ | A Trial of Tisotumab Vedotin in Cervical Cancer | Active, not recruiting | European Network of Gynaecological Oncological Trial Groups (ENGOT) | Phase 2 | 2018-06-12 | A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. |
NCT03438396 ↗ | A Trial of Tisotumab Vedotin in Cervical Cancer | Active, not recruiting | Genmab | Phase 2 | 2018-06-12 | A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. |
NCT03438396 ↗ | A Trial of Tisotumab Vedotin in Cervical Cancer | Active, not recruiting | Gynecologic Oncology Group | Phase 2 | 2018-06-12 | A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. |
NCT03438396 ↗ | A Trial of Tisotumab Vedotin in Cervical Cancer | Active, not recruiting | Seattle Genetics, Inc. | Phase 2 | 2018-06-12 | A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TIVDAK
Condition Name
Clinical Trial Locations for TIVDAK
Trials by Country
Clinical Trial Progress for TIVDAK
Clinical Trial Phase
Clinical Trial Sponsors for TIVDAK
Sponsor Name